• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    11/13/23 4:06:01 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DFFN alert in real time by email
    crvo20231113_8k.htm
    false 0001053691 0001053691 2023-11-13 2023-11-13
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of The Securities Exchange Act of 1934
     
    November 13, 2023
    Date of Report (Date of earliest event reported)
     

     
    CervoMed Inc.
    (Exact name of registrant as specified in its charter)
     

     
    Delaware
     
    001-37942
     
    30-0645032
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
       
    20 Park Plaza, Suite 424
    Boston, Massachusetts
     
    02216
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (617) 744-4400
     
    Not applicable
    (Former name or former address, if changed since last report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.001 par value
     
    CRVO
     
    NASDAQ Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     
     

     
     
    Item 2.02         Results of Operations and Financial Condition
     
    Earnings Press Release
     
    On November 13, 2023, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the period ended September 30, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
     
    The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.
     
    Item 7.01. Other Events
     
    Corporate Presentation
     
    Certain information concerning the Company’s business, clinical studies, development plans, financial position and related matters of has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.
     
    The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.
     
    The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as set forth by specific reference in such a filing.
     
    Item 9.01         Financial Statements and Exhibits
     
    (d)         Exhibits
     
    Exhibit No.
     
    Description
         
    99.1
     
    Press Release, issued November 13, 2023
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: November 13, 2023
    CervoMed Inc. 
     
           
     
    By:
    /s/ William Elder
     
     
    Name: 
    William Elder 
     
     
    Title: 
    General Counsel 
     
     
     
    Get the next $DFFN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFFN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DFFN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

    Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to

    8/15/23 4:01:02 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

    Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D

    3/30/23 7:00:20 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

    LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert

    12/16/22 6:30:48 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    Leadership Updates

    Live Leadership Updates

    View All

    Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

    CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adju

    5/18/22 7:30:00 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update. Business Updates Completed Dosin

    5/12/22 4:05:00 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    SEC Filings

    View All

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    2/7/24 4:06:21 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    2/2/24 4:17:13 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    1/5/24 4:05:35 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)

    SC 13G/A - CervoMed Inc. (0001053691) (Subject)

    2/14/24 9:23:50 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Diffusion Pharmaceuticals Inc.

    SC 13D - CervoMed Inc. (0001053691) (Subject)

    2/9/24 5:02:49 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Diffusion Pharmaceuticals Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    8/28/23 4:02:26 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Boger Joshua S

    4 - CervoMed Inc. (0001053691) (Issuer)

    2/13/24 4:39:58 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Boger Joshua S claimed ownership of 561,309 shares (SEC Form 3)

    3 - CervoMed Inc. (0001053691) (Issuer)

    2/9/24 4:31:45 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Alam John J

    4 - CervoMed Inc. (0001053691) (Issuer)

    1/26/24 6:47:52 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care